ABVCライブシグナル | Getagraph.comで利益を最大化

買う 115311 min ago

@ $1.300

発行日: 9 2月 2024 @ 03:07

リターン: 9.23%

前回のシグナル: 2月 7 - 23:30

前回のシグナル: 売る

リターン: -7.80 %

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States...

Stats
本日の出来高	2.03M
平均出来高	1.08M
時価総額	15.00M
EPS	$0 ( 2024-03-29 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.580
ATR14	$0.0200 (1.39%)

Insider Trading

Date	Person	Action	type
2022-05-20	Jiang Shuling	Buy	Common Stock
2021-08-02	An Chihliang	Sell	Common Stock
2021-08-02	Sakamoto Norimi	Buy
2021-08-02	Odaira Yoshinobu	Sell	Common Stock
2021-08-02	Jiang Tsung Shann	Buy	Common Stock

INSIDER POWER
0.00
Last 77 transactions
Buy: 22 119 096 \| Sell: 9 170 000

ボリューム相関

長: 0.30 (neutral)

短: -0.56 (weak negative)

Signal:(38.229) Neutral

AMERICAN BRIVISION 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

AMERICAN BRIVISION 相関 - 通貨/商品

0.15
( neutral )

0.43
( neutral )

0.00
( neutral )

0.18
( neutral )

AMERICAN BRIVISION 財務諸表

Annual	2023
収益:	$152 430
総利益:	$-178 138 (-116.87 %)
EPS:	$-2.43

FY	2023
収益:	$152 430
総利益:	$-178 138 (-116.87 %)
EPS:	$-2.43

FY	2022
収益:	$969 783
総利益:	$683 368 (70.47 %)
EPS:	$-5.15

FY	2021
収益:	$355 797
総利益:	$350 711 (98.57 %)
EPS:	$-0.510

Financial Reports:

No articles found.

AMERICAN BRIVISION

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.